Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Glioblastoma 2Spondylitis, Ankylosing 1Signs and Symptoms 1Psoriasis 1Nutrition Disorders 1Lymphoma 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Inflammatory Bowel Diseases 1Glioma 1Gastroparesis 1Feeding and Eating Disorders 1Esophageal Neoplasms 1Epilepsy 1Dumping Syndrome 1Diarrhea 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 401Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 138Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Sulfasalazine × Clear all
NCT03847311 2025-01-09

Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients

University of Arizona

Phase 2 Completed
7 enrolled 8 charts
Breast

Breast Neoplasms, Signs and Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡